肝癌组织中NM23的表达及其临床意义

Expression of NM23 in hepatocareinoma and its clinical significance

目的了解肿瘤抑制基因NM23与肝癌临床分期间的关系。方法应用免疫组织化学SP法（Streptavid in Peroxidase）,检测石蜡包埋的肝细胞癌组织120例,其中临床Ⅰ～Ⅱ期60例,Ⅲ～Ⅳ期60例,及30例正常肝组织作为对照组。结果NM23在正常对照组的阳性表达率为80%,肝细胞癌组织中阳性率为29.1%,正常对照组与肝细胞癌组织差异有统计学意义,但临床Ⅰ～Ⅱ期与Ⅲ～Ⅳ期阳性表达率之间无统计学意义。结论检测NM23可为评价肝癌的生物学行为和临床治疗提供一定的依据,对肿瘤的诊断及预后的评估有积极的临床意义。

Objective To study the clinical significance of NM23 in Hepatocarcinom. Methods One hundred and twenty hepatocarcinoma samples were determined by immunohistochemical staining（ Streptavidin Peroxidase method） in paraffin -embeded specimens. It included clinical stage Ⅰ - Ⅱ 60 samples, stage Ⅲ - Ⅳ 60 samples. Results The positive rate of NM23 expression in control group and hepatocarcinoma were 80% ,29. 1% respectively. It had significiant difference between control group and hepatocarcinoma group （P 〈 0. 05）. No significiant difference was found between clinical stage Ⅰ - Ⅱ and clinical stage Ⅲ - Ⅳ. Conclusion NM23 might be useful to evaluate the biological behavior of hepatocarcinoma and evaluate prognosis in hepatocarcinoma.